Skip to main content
Download PDF
- Main
Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- Wu, Jing;
- Yuan, Ying;
- Priel, Debra A Long;
- Fink, Danielle;
- Peer, Cody J;
- Sissung, Tristan M;
- Su, Yu-Ting;
- Pang, Ying;
- Yu, Guangyang;
- Butler, Madison K;
- Mendoza, Tito R;
- Vera, Elizabeth;
- Ahmad, Salman;
- Bryla, Christine;
- Lindsley, Matthew;
- Grajkowska, Ewa;
- Mentges, Kelly;
- Boris, Lisa;
- Antony, Ramya;
- Garren, Nancy;
- Siegel, Christine;
- Lollo, Nicole;
- Cordova, Christine;
- Aboud, Orwa;
- Theeler, Brett J;
- Burton, Eric M;
- Penas-Prado, Marta;
- Leeper, Heather;
- Gonzales, Javier;
- Armstrong, Terri S;
- Calvo, Katherine R;
- Figg, William D;
- Kuhns, Douglas B;
- Gallin, John I;
- Gilbert, Mark R
- et al.
Published Web Location
https://doi.org/10.1158/1078-0432.ccr-20-4730Abstract
Purpose
To investigate the toxicity profile and establish an optimal dosing schedule of zotiraciclib with temozolomide in patients with recurrent high-grade astrocytoma.Patients and methods
This two-stage phase I trial determined the MTD of zotiraciclib combined with either dose-dense (Arm1) or metronomic (Arm2) temozolomide using a Bayesian Optimal Interval design; then a randomized cohort expansion compared the progression-free survival rate at 4 months (PFS4) of the two arms for an efficient determination of a temozolomide schedule to combine with zotiraciclib at MTD. Pharmacokinetic and pharmacogenomic profiling were included. Patient-reported outcome was evaluated by longitudinal symptom burden.Results
Fifty-three patients were enrolled. Dose-limiting toxicities were neutropenia, diarrhea, elevated liver enzymes, and fatigue. MTD of zotiraciclib was 250 mg in both arms and thus selected for the cohort expansion. Dose-dense temozolomide plus zotiraciclib (PSF4 40%) compared favorably with metronomic temozolomide (PFS4 25%). Symptom burden worsened at cycle 2 but stabilized by cycle 4 in both arms. A significant decrease in absolute neutrophil count and neutrophil reactive oxygen species production occurred 12-24 hours after an oral dose of zotiraciclib but both recovered by 72 hours. Pharmacokinetic/pharmacogenomic analyses revealed that the CYP1A2_5347T>C (rs2470890) polymorphism was associated with higher AUCinf value.Conclusions
Zotiraciclib combined with temozolomide is safe in patients with recurrent high-grade astrocytomas. Zotiraciclib-induced neutropenia can be profound but mostly transient, warranting close monitoring rather than treatment discontinuation. Once validated, polymorphisms predicting drug metabolism may allow personalized dosing of zotiraciclib.Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
For improved accessibility of PDF content, download the file to your device.
Enter the password to open this PDF file:
File name:
-
File size:
-
Title:
-
Author:
-
Subject:
-
Keywords:
-
Creation Date:
-
Modification Date:
-
Creator:
-
PDF Producer:
-
PDF Version:
-
Page Count:
-
Page Size:
-
Fast Web View:
-
Preparing document for printing…
0%